Wednesday - April 30, 2025
KALAMAZOO, Michigan, USA, March 2, 2023 /PRNewswire/ -- Stryker (NYSE:SYK) announced the launch of its CD NXT System, the latest innovation in the company's power tools. This patented technology provides real-time depth measurement as the surgeon drills, allowing for fast, accurate, consistent digital depth measurement across various procedures.
CD NXT streamlines instrumentation and surgical steps, offering an accurate and reproducible measurement while removing errors commonly associated with a manual depth gauge. The system works independently of the implant system, allowing broad use across the market.
"We continuously listen to the needs and pain points of our customers. We discovered the need for a more accurate and dependable depth measurement tool through research. CD NXT fills that gap through a revolutionary technology allowing the power tool to communicate information back to the surgeon, enabling real-time decision-making," said Bill Scott, vice president and general manager of Stryker's Orthopaedic Instruments business.
CD NXT features include:
For more information, including videos, please visit Stryker's CD NXT System product page at https://www.stryker.com//us/en/orthopaedic-instruments/products/cd-nxt.html
About Stryker
Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.
Media contact
Beth Sizemore
Sr. Director, Strategic Communications
Instruments
beth.sizemore@stryker.com
Last Trade: | US$373.92 |
Daily Change: | 3.00 0.81 |
Daily Volume: | 2,159,145 |
Market Cap: | US$142.550B |
March 04, 2025 March 03, 2025 January 28, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load